Pharmacological Effects of Eupatilin in Cancer Treatment

Eupatilin, a naturally occurring flavonoid derived primarily from Artemisia species, exerts multifaceted antitumour actions across a range of malignancies. In vitro and in vivo studies demonstrate that eupatilin impairs cancer cell viability through induction of apoptosis and cell cycle arrest, often at the G2/M transition. Its mechanisms encompass mitochondrial dysfunction with loss of membrane potential, generation of reactive oxygen species and activation of endoplasmic reticulum stress pathways. Eupatilin also modulates key signalling cascades, notably inhibiting the PI3K/AKT and mitogen-activated protein kinase pathways, and it can downregulate oncogenic microRNAs while restoring tumour-suppressive targets. In animal models, eupatilin reduces tumour growth and angiogenesis with minimal adverse effects, and it shows synergistic potential when combined with conventional chemotherapeutics. These properties point to eupatilin as a promising adjuvant or stand-alone agent for diverse cancer types, offering a natural compound with low toxicity and broad therapeutic reach.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Effects of Eupatilin in Cancer Treatment publication trend

The graph below shows the total number of articles in pharmacological effects of eupatilin in cancer treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Apoptosis: Programmed cell death characterised by caspase activation and DNA fragmentation.

Mitochondrial depolarisation: Loss of the electrochemical gradient across the mitochondrial membrane, leading to energy failure and apoptosis.

Endoplasmic reticulum (ER) stress: Cellular condition in which unfolded proteins accumulate in the ER, triggering stress response pathways.

Autophagy: Intracellular degradation process that recycles cytoplasmic components and can contribute to cell survival or death in cancer.

PI3K/AKT pathway: Signalling cascade involved in cell growth and survival, frequently hyperactivated in tumours.

Mitogen-activated protein kinase (MAPK) pathway: Series of kinases regulating proliferation, differentiation and apoptosis in response to extracellular signals.

SERPINB11: A serine protease inhibitor whose downregulation by eupatilin promotes calcium-mediated apoptotic signalling.

References

1. Eupatilin Inhibits Renal Cancer Growth by Downregulating MicroRNA‐21 through the Activation of YAP1. BioMed Research International (2019).
2. Eupatilin: A flavonoid compound isolated from the artemisia plant, induces apoptosis and G2/M phase cell cycle arrest in human melanoma A375 cells. African Journal of Pharmacy and Pharmacology (2011).
3. Eupatilin Impacts on the Progression of Colon Cancer by Mitochondria Dysfunction and Oxidative Stress. Antioxidants (2021).
4. Eupatilin Promotes Cell Death by Calcium Influx through ER-Mitochondria Axis with SERPINB11 Inhibition in Epithelial Ovarian Cancer. Cancers (2020).
5. Comparative Evaluation of Anticancer Activity of Natural Methoxylated Flavones Xanthomicrol and Eupatilin in A375 Skin Melanoma Cells. Life (2024).